case_images: PMC10991726_01
case_images: The changing trends of PSA and testosterone levels over time in four patients.
case_images: fonc-14-1374039-g001.jpg
case_images: PMC10991726_04_fonc-14-1374039-g001.jpg
case_images: f1
case_images: However, PSA rose to 133.297 ng/ml by December 5 (Shown in  Figure 1 ), suggesting metastatic castration-resistant prostate cancer (mCRPC).
case_images: PMC10991726_02
case_images: The changing trends of PSA and testosterone levels over time in four patients.
case_images: fonc-14-1374039-g001.jpg
case_images: PMC10991726_04_fonc-14-1374039-g001.jpg
case_images: f1
case_images: However, PSA rose to 133.297 ng/ml by December 5 (Shown in  Figure 1 ), suggesting metastatic castration-resistant prostate cancer (mCRPC).
case_images: PMC10991726_03
case_images: The changing trends of PSA and testosterone levels over time in four patients.
case_images: fonc-14-1374039-g001.jpg
case_images: PMC10991726_04_fonc-14-1374039-g001.jpg
case_images: f1
case_images: However, PSA rose to 133.297 ng/ml by December 5 (Shown in  Figure 1 ), suggesting metastatic castration-resistant prostate cancer (mCRPC).
case_images: PMC10991726_04
case_images: The changing trends of PSA and testosterone levels over time in four patients.
case_images: fonc-14-1374039-g001.jpg
case_images: PMC10991726_04_fonc-14-1374039-g001.jpg
case_images: f1
case_images: However, PSA rose to 133.297 ng/ml by December 5 (Shown in  Figure 1 ), suggesting metastatic castration-resistant prostate cancer (mCRPC).